News and Trends 7 Dec 2022 BiVictriX identifies development lead for ADC cancer program BiVictriX Therapeutics plc, an emerging biotechnology company applying a novel approach to develop next generation cancer therapies using insights derived from frontline clinical experience, has identified a development lead for its BVX001 program. The lead was developed using BiVictriX’s proprietary Bi-Cygni approach, which aims to generate the next-generation of antibody drug conjugates (ADCs) with superior […] December 7, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Dec 2022 Scientists identify genetic variant causing ALS in some patients Researchers at Nagoya University in Japan have identified a novel genetic variant found in some patients with amyotrophic lateral sclerosis (ALS). Employing human-induced pluripotent stem (iPS) cells, they detailed the process by which this variant relates to ALS. The investigators say they expect this mechanism to be a new therapeutic target for ALS treatment. The […] December 7, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Dec 2022 Rani Therapeutics reveals results from phase 1 osteoporosis study Rani Therapeutics Holdings, Inc., a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, has announced topline results from part 2 (the repeat-dose portion) of the phase 1 study of RT-102, the RaniPill GO capsule containing a proprietary formulation of human parathyroid hormone (1-34) analog (PTH) being developed for the treatment of […] December 7, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Dec 2022 FDA clears insulin pen medical device BIOCORP, a French company specialized in the design, development, and manufacturing of innovative medical devices, has received 510(K) clearance from the U.S. Food & Drug Administration (FDA) to market Mallya, its smart medical device that connects insulin pens. Eric Dessertenne, CEO of BIOCORP, said: “This approval is a major achievement for BIOCORP and all of […] December 7, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Dec 2022 Tetra announce significant results from the study of Onternabez combined with Favipiravir Tetra Bio-Pharma Inc. a leader in cannabinoid-derived drug discovery and development announced today significant results from the study of Onternabez combined with Favipiravir. The combination acts against ARDS (acute respiratory distress syndrome), Sepsis, and Covid-19 through PREPAiRE, an artificial intelligence (AI) powered platform. The platform, the companies say, purposely integrates target identification, validation, lead discovery […] December 6, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 6 Dec 2022 INSPIRE launched to develop inhaled gene therapy for the treatment of lung cancer OmniSpirant Limited and EVerZom have launched INSPIRE, a €12.8 million ($13.4 million) lung cancer project funded by Horizon Europe. In one of the largest ever grants for preclinical research in lung cancer, OmniSpirant and its European partners in biotechnology, medical devices, cancer research, academia and patient advocacy, met in Galway, Ireland, for the official kick-off […] December 6, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Dec 2022 Entact Bio launches with $81M to develop precision medicines Entact Bio has raised $81 million in series A financing to advance its proprietary Encompass platform for developing enhancement-targeting chimeric (ENTAC) molecules. The round was co-led by Qiming Venture Partners USA and venBio Partners, with participation by new investors Abingworth, Brandon Capital, Janus Henderson Investors, Logos Capital, Surveyor Capital (a Citadel company), and WEHI (Walter […] December 6, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Dec 2022 Avalon BioVentures to invest in early-stage biotech L.P., a venture capital firm dedicated to early-stage biomedical innovation, has closed its first venture fund, ABV1, with $135 million in funding from new and existing institutional investors. Avalon BioVentures emerged from Avalon Ventures’ shared life-science/high-tech investing funds as a life-science only fund and will continue to leverage Avalon’s team and company accelerator to create, […] December 6, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Dec 2022 Pictor receives $5M in funding for Covid antibody test and human and animal portfolios Pictor, a global leader in immunodiagnostics, has announced a $5 million funding round to help accelerate pipeline product development projects. The company will also use the funding for market development activities within Australia and New Zealand, the U.S. and Europe for its human health and animal health portfolios. This follows a June funding round raising […] December 6, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 6 Dec 2022 New brain tumor subtypes discovery may help develop treatments for incurable brain cancer Research led by RCSI University of Medicine and Health Sciences in Ireland has discovered three new subtypes of brain tumor. This could help to identify new and effective therapies. The novel tumor subtypes are forms of glioblastoma, the most common and most aggressive form of adult primary brain cancer with no cure currently available. The […] December 6, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Dec 2022 ImaginAb launching clinical trial for renal cancer and malignant melanoma ImaginAb Inc., which is focused on developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPET) imaging agent and radiopharmaceutical therapy (RPT) products, is starting a phase II clinical trial. The trial, PRETZCEL, which will take place at Hull University Teaching Hospitals NHS Trust in the U.K., will investigate ImaginAb’s investigational CD8 ImmunoPET agent in patients with melanoma or […] December 6, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Dec 2022 Positive results from BioAge muscle atrophy trial BioAge Labs, Inc. has announced positive phase 1b clinical data for BGE-105, a highly selective, potent, orally available small-molecule agonist of the apelin receptor APJ. BGE-105 treatment resulted in statistically significant prevention of muscle atrophy relative to placebo in healthy volunteers aged 65 or older after 10 days of strict bed rest. Muscle atrophy—loss of […] December 6, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email